The global cardiovascular drug market is undergoing a pivotal transformation, as Novartis’ blockbuster cardiovascular medication, Sacubitril Valsartan Sodium Tablets (brand name: Entresto/诺欣妥), lost its US patent protection in July 2025, with its core patent in China set to expire fully in 2026. Regarded as a milestone drug in the field of heart failure treatment, this branded medication has long dominated the core share of the global and domestic cardiovascular drug market thanks to its exceptional clinical efficacy. With the collapse of patent barriers, the domestic generic drug market has heated up rapidly; at present, 33 domestic pharmaceutical companies have successfully passed the consistency evaluation for their generic versions, fully prepared to seize the market share of this blockbuster drug valued at over ten billion yuan, marking a window for the restructuring of the industry landscape.

Core Ingredient Valsartan: The Cornerstone of Entresto’s Efficacy, an Indispensable API in the Cardiovascular Field

As a compound preparation, the core therapeutic effect of Sacubitril Valsartan Sodium Tablets relies on the synergistic effect of its two key ingredients, among which valsartan is an irreplaceable active pharmaceutical ingredient (API) and the core support for the drug’s antihypertensive and heart failure treatment functions. Valsartan is a classic angiotensin II receptor antagonist (ARB) antihypertensive drug with mature clinical applications. It is not only the core component of Entresto but also a first-line medication independently used for the treatment of essential hypertension, heart failure and other cardiovascular diseases. It boasts a wide applicable population, high clinical recognition, and steady growth in market demand year-round.

From the perspective of the pharmaceutical industry chain, API is the core upstream raw material for generic drug production. The quality, supply stability and cost advantage of valsartan API directly determine the production efficiency, product quality and market competitiveness of downstream generic drug enterprises. Following the patent expiry of Entresto, domestic generic drug manufacturers have accelerated mass production, and coupled with the sustained market demand for single-agent valsartan preparations, the global demand for high-purity, compliant valsartan API has surged exponentially. Stable and high-quality API supply has become a core bargaining chip for pharmaceutical enterprises to compete in the market.

Seize Market Dividends: Our Company’s One-Stop Supply of Valsartan API and Indian Generic Drugs

Keeping pace with the transformative trends in the cardiovascular drug market and focusing on core industry demands, our company has been deeply engaged in the pharmaceutical raw material and generic drug supply chain for many years. We specialize in providing a one-stop supply service for valsartan API and compliant Indian valsartan generic drugs, precisely matching the procurement needs of domestic pharmaceutical companies and pharmaceutical circulation enterprises. We help partners seize the market dividends brought by Entresto’s patent expiry and achieve efficient and compliant raw material and product supply.

1. Valsartan API: High Purity, Full Compliance, and Stable Supply Guarantee

• Strict Quality Control: The valsartan API supplied by our company strictly adheres to international pharmaceutical production standards, featuring qualified purity and controllable impurity content. It fully complies with the requirements of the Chinese Pharmacopoeia and major international pharmacopoeias, suitable for various scenarios including consistency evaluation declaration for generic drugs and large-scale production. We ensure the safety and effectiveness of downstream preparation products from the source.

• Reliable and Stable Supply Chain: We have established direct supply channels with high-quality overseas production bases, avoiding risks such as raw material price hikes and supply disruptions. With large-scale supply capacity, we can flexibly adjust procurement volumes according to customer needs, providing rapid response and on-time delivery for both small-batch trial production and large-scale regular procurement, and fully safeguarding customers’ production schedules.

• Outstanding Cost-Effectiveness: Relying on a mature overseas procurement system and large-scale procurement advantages, we reduce intermediate circulation links to offer customers highly competitive prices, effectively lowering the production costs of downstream generic drug enterprises and enhancing their profit margins in the market.

2. Indian Valsartan Generic Drugs: Fully Compliant, Cost-Effective, and Adaptable to Diverse Market Needs

As a major global producer of generic drugs, India has sophisticated preparation production processes and strict quality control systems. Valsartan generic drugs produced in India are highly consistent with branded drugs in therapeutic efficacy, yet priced far lower, combining both efficacy and cost advantages. Our company selects valsartan generic drugs produced by leading compliant Indian pharmaceutical companies, with complete qualifications and traceable compliance. These products are suitable for multiple channels including hospital clinics, primary medical care and pharmaceutical circulation, providing partners with cost-effective preparation options to further expand their market layout.

Industry Boom Has Arrived: Join Hands to Explore the Blue Ocean of the Cardiovascular Drug Market

The patent expiry of Entresto has fully unlocked the growth potential of the cardiovascular generic drug market, and the market demand for valsartan, as the core API, will continue to rise. Whether downstream generic drug manufacturers need stable and high-quality API to ensure production, or circulation enterprises plan to layout cost-effective valsartan preparations, our company can provide professional, compliant and efficient supply chain solutions.

Adhering to the philosophy of "Quality First, Integrity and Win-Win Cooperation", we have a professional pharmaceutical industry team that provides one-stop services including qualification review, logistics and transportation, and after-sales coordination throughout the process. We help partners avoid pain points in the supply chain, quickly enter the market, and seize the first-mover advantage after patent expiry. We welcome major pharmaceutical companies and distributors to discuss cooperation, join hands to share the hundreds of billions of dividends in the cardiovascular drug market, and build a compliant and efficient pharmaceutical supply chain ecosystem together!